**Trump Nominates Heidi Overton as FDA Commissioner**
**Washington, D.C.** – President Donald Trump has officially nominated Dr. Heidi Overton to lead the U.S. Food and Drug Administration (FDA), a critical agency responsible for ensuring food safety, drug standards, and public health. The announcement was made on August 19, 2026, via a post on Trump's social media platform, Truth Social.
In his statement, Trump praised Overton, describing her as a “ROCKSTAR” in his administration. He highlighted her previous work as a policy aide and her role at the America First Policy Institute, a think tank aligned with Trump’s political agenda. Trump emphasized that Overton would prioritize “America First” policies at the FDA, aiming to address key health issues facing the nation.
“Today I am honoured to nominate the wonderful Dr. Heidi Overton, MD, PhD, as our next FDA Commissioner,” Trump wrote. “Dr. Heidi has been a ROCKSTAR in my Administration, where she has worked directly with [Health and Human Services] Secretary Kennedy, Dr. Oz, and team, to deliver on the MOST TRANSFORMATIVE Health Agenda in History. She is known to take on the HARDEST issues, and bring me solutions that work best for the Country.”
Overton’s nomination comes at a time when the FDA is experiencing a leadership transition, following the resignation of former Commissioner Dr. Marty Makary in May. As the nominee, Overton will need to secure confirmation from the U.S. Senate before officially taking on the role.
Dr. Overton holds a medical degree from the University of New Mexico and a doctorate in clinical investigation from Johns Hopkins University. Her background in medicine and policy positions her as a knowledgeable candidate for the FDA leadership role. Prior to her appointment in the Trump administration, she served as chief policy officer at the America First Policy Institute, where she focused on advancing Trump’s health-related initiatives.
Throughout her tenure, Overton has been a vocal critic of abortion pills, aligning herself with anti-abortion activists who advocate for increased restrictions on access to these medications. Her stance on this issue reflects the broader ideological battles surrounding reproductive health in the United States.
In addition to her work on reproductive health, Overton has been involved in efforts to create “most favoured nation” agreements with pharmaceutical companies, a strategy aimed at reducing drug prices for American consumers. Trump has indicated that Overton will play a significant role in advancing this initiative, along with other key promises made during his administration.
The nomination of Overton is indicative of the Trump administration’s ongoing challenges with health agencies, where there has been notable tension between the administration and scientific experts. Critics have raised concerns about the administration's approach to public health issues, particularly regarding vaccines and other health policies that diverge from established scientific consensus.
As the nomination process unfolds, Overton's confirmation will be closely watched by both supporters and critics of the Trump administration. Her leadership at the FDA could have significant implications for public health policy and regulatory practices in the United States.
The FDA, established in 1906, plays a vital role in protecting public health by ensuring the safety and efficacy of food, drugs, and medical devices. The agency's decisions can have far-reaching effects on healthcare, consumer safety, and pharmaceutical innovation.
As the Senate prepares to consider Overton's nomination, discussions will likely focus on her qualifications, her previous work in the Trump administration, and her positions on key health issues. The outcome of this nomination could shape the future direction of the FDA and its role in American health policy.